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   Abstract 
Nephrolithiasis, or urolithiasis, commonly known as kidney stones, is a common medical problem. 
Kidney stones are composed of different mineral types. Calcium Oxalate is the most common 
kind of stone. 
The principal aim of this research was to establish whether hydroxycitrate (HCA) affects and/or 
inhibits calcium oxalate crystallisation. A three-pronged approach was adopted, involving the 
determination of thermodynamic binding constants for Ca, Mg and Zn-HCA complexes, 
theoretical modelling of HCA-complex formation in artificial urine and in vitro crystallisation 
experiments. A potentiometric analysis was conducted to determine thermodynamic binding 
constants. These were included in the database of the JESS computer program to model the effect 
of HCA on the urinary supersaturation of calcium salts.   A 1 mM HCA concentrations 
successfully decreased the concentration of ionised calcium and hence the urinary 
supersaturation of calcium salts. The solution structures of H+, Ca 2+, Mg 2+, and Zn 2+-HCA 
complexes were investigated using 
1H-NMR. For protonation, the results showed that the pKa
values were too close to resolve and that several microstates were in rapid exchange. Similarly, 
for the metal complexes, several species were found to be in rapid exchange. Crystallisation 
experiments were conducted in artificial urine, to determine the effect of HCA on the 
thermodynamics and kinetics of crystallisation of calcium oxalate, which is the most common 
component of kidney stones. The effect of HCA on calcium oxalate metastable limit (MSL) and 
crystallisation kinetics were measured. The results confirmed those predicted by theoretical  
IV 
modelling. The MSL was significantly affected by 1 mM HCA. Also, 1 mM HCA increased the 
rate of CaOx crystallisation. Both these effects are favourable and decrease the risk of in vivo  
crystal and stone formation. This augurs well for the potential application of HCA as a 
therapeutic agent in the management of kidney stone disease. Such an outcome needs to be tested 
in human trials.
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              1.   Kidney Stone Disease 
1.1. Background of the Disease 
Nephrolithiasis, or urolithiasis, commonly known as kidney stones, is a common medical 
problem.[1] [2] Kidney stones can be described as pieces of solid material produced inside the 
kidney, in addition to normal urine constituents. Large stones may block the ureter, bladder, or 
urinary tract, thus potentially retarding urine excretion. [3] Stone formation is a variegated 
process comprising nucleation, growth of crystal, and aggregation. [4] 
The epidemiology of urolithiasis varies according to the geographical area, age, and gender of the 
patients. [5] 
The prevalence of kidney stones is 10% in males and 6% in females. [6] It increases with age, 
peaking in those aged 40 to 59 years. [7] 
Kidney stones affect some 5 - 15% of the inhabitants worldwide [8] with higher incidences observed 
in Caucasian patients, followed by Hispanics, Africans, and Asians. [9] 
1.2. Composition of stones 
Approximately 80 % of all stones are made up of calcium oxalate (CaOx) and calcium phosphate 
(CaP). Urinary calcium concentrations that are 7-11 times higher than normal raise the risk of 
Ca-containing kidney stones.  [10-14] Calcium phosphate (Cap) stones account for nearly 15% of all 
urinary stones with a noticeable preponderance in females.  [15]       
 





 Although most kidney stones contain primarily calcium oxalate, up to 50% of these, contain 
calcium hydroxyl phosphate (10–20%), magnesium ammonium phosphate (struvite or triple 
phosphate), urate (5%), and 1–2% comprises cysteine. Ideally, a stone analysis should be 
performed via infrared spectroscopy or x-ray diffraction. [14, 16] A kidney stone may form when 
high levels of calcium, oxalate, uric acid, or cysteine are excreted in the urine. [14] Stones may 
also form if these compounds are present at normal levels, but urine flow is restricted. [13] 
Supersaturation of these substances leads to crystals, which may become anchored in the kidney 
and grow (crystal growth) to form a kidney stone. [17] 
The prevalence of kidney stones in end-stage renal disease (ESRD) [7] is 5.2% in the United 
States.  African-Americans, who are a minority (12.9%) make up > 30% of patients progressing 
to ESRD. [18] However, in general, this group has a three-fold lower prevalence of kidney stones 
than the rest of the US population. [19] 
The black South African population also shows a lower overall prevalence of urinary stones than 
their white counterparts. [19, 20] 
People have suffered from kidney and bladder stones for centuries. [21] Its prevalence is 12% in 
Canada, 5 - 9% in Europe, and 13 - 15% in the US. While it is only 1 - 5% in most Eastern 
countries, the risks are much higher in certain Asian countries. Saudi Arabia has an occurrence 
rate of 20.1%, with a lifetime repetition rate of up to 50 %. [14]   
 




Stones produce without any symptoms or clinical signs until significant stone growth results in 
hematuria. Stone passage begins as mild uneasiness but progresses to extreme pain over 30–60 
min. [14] If the stone blocks the ureteropelvic junction, the pain localises in the flank, and, as the 
stone shifts down the ureter, the pain transfers downward towards the anterior side. [22] Once the 
stone reaches the ureters vesicular junction, it may cause dysuria, and symptoms may be 
mistaken for those of infection. [14] Stones less than 5 mm in diameter have a greater chance of 
passage, those 5–7 mm in diameter have a moderate chance (60%) of passage, and those greater 
than 7 mm in diameter usually cannot pass on their own and require urological intervention. 
[16][14]  
1.3. Mechanism of stone formation 
Various studies have attempted to discern the mechanism of CaOx kidney stone formation. 
Kidney stones are produced from the growing of crystals to stones, and the physical process of 
stone formation involves the following complex cascade of events and physicochemical processes: 
Saturation → Supersaturation → Nucleation → Crystal aggregation 
Crystal growth → Crystal retention → Stone formation 
 Supersaturation is essential for stone formation. [23] 
The multifactorial aetiology of kidney stone formation and high rates of recurrence have resulted 
in a long-standing interest in the potential role of macromolecules in nephrolithiasis, particularly 
considering all human stones in the kidneys consist of a complex mixture of mineral and organic 
materials. [5] 
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The major types of stones and their mechanisms of formation are as follows. 
1.3.1. Calcium oxalate (CaOx) 
Calcium oxalate (CaOx ) stones are of two types: the monohydrate, and the dihydrate. Calcium oxalate 
monohydrate (COM) is observed to recur in patients with normal urine calcium excretions; these crystals 
could arise because of an absence or deficiency of inhibitors thereby allowing crystals to form and pass 
spontaneously in the urine.  In contrast, calcium oxalate dihydrate (COD) is found in patients with high urine 
calcium and no elevation in citrate excretion or urinary pH. [24] COD can also be found in combination with 
uric acid or calcium phosphate. CaOx stones grow in the papillary tip, on Randall's plaque, [12] [21 ]   and so the 
core of the stones may be CaP (usually 5%) surrounded by CaOx (95%). 
Hypercalciuria occurs when a pathological process produces excessive urinary calcium. [12, 25] 
Hyperoxaluria is increased urinary excretion of oxalate. Two distinct forms of hyperoxaluria exist. 
Primary hyperoxaluria is a metabolic error, while secondary hyperoxaluria is a result of increased 
dietary ingestion of oxalate, oxalate precursors or changes in intestinal microflora. [26] 
Hypocitraturia is defined as low citrate secretion. [27] Hypocitraturia may be associate with 
hypercalciuria or occurs as an abnormality. Potassium citrate can be used as therapy, but some 
patients are affected by gastrointestinal side-effects, particularly dyspepsia. [28] 
 
1.3.2. Phosphate stones 
Phosphate stone occure as carbonate-apatite, brushite, hydroxyapatite , whitlockite and struvite,or 
a mixture of these. [29, 30]     
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Hydroxyapatite make up 9.5 % of stones,  brushite 2.1 % and struvite infection stones 14.6 %. 
Stones resulting from infection are 20-60 % struvite with the remaining part comprising 
hydroxyapatite and or calcium-deficient hydroxyapatite as the Ca/P ratio varies between 1.3 and 
1.6. [24] 
 
1.3.3. Brushite (CaHPO4·2H2O) stones 
Brushite is named after the American mineralogist George Jarvis Brush and is the dominant phase 
of the CaHPO4·2H2O system that precipitates between pH 2 and pH 6.5.
 [31] These stones have a 
Ca/P molar ratio that is close to unity. Brushite precipitates from urine containing 60 mg/L of 
magnesium at pH < 7.0. [32] While brushite is the principal component of brushite stones they may 
also contain as much as 10 % hydroxyapatite.   Brushite stones contain numerous cavities, 
partially filled with organic matter and/or hydroxyapatite. [24]   Nucleated crystals grow from 
supersaturated urine by depositing growth units. [32, 33] These formations are composed of 
individual crystals. [34]  
 
1.3.4. Uric acid stones 
Uric acid stones make up approximately 13% of human kidney stones. These stones can be 
categorised into two distinct subtypes depending on their structure: 
Compact uric stones (type I) are mainly formed by crystalline growth of anhydrous uric acid 
(UAA) and may include small urine deposits; this kind could be further divided into two stone 
subgroups. [35] 
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Type II stones consist of stones formed usually by sedimentation and could be divided into two 
groups. 
(1) IIa stones have a porous interior, which is filled with UAA, COM or organic matter. [35] 
(2) IIb stones were initially uric acid dihydrate (UAD) which later changed to UAA. Their 
interior is either empty or partially filled with crystals or organic matter. [35] 
Urinary stones may also be typified according to their position in the urinary system and may be 
located in the kidney, pelvis, urethra or bladder (Figure 1.1) 
 
Figure 1.1. The major site of kidney stones according to the position in the urinary system. [36] 
 
1.4. Kidney stone treatment 
Kidney stone treatment and prevention consists of the following three approaches. [37] 
 
 




1.4.1. Dietary recommendations 
Adequate dietary calcium intake should be maintained, but dietary oxalate should be restricted 
because dietary oxalate may be significant in stone development and could be raise urinary oxalate 
secretion and predispose to the development of CaOx. [38-42] 
Animal protein and salt consumption should be decreased because more than normal animal 
protein intake contributes to hyperuricosuria, a peril for calcium stones [43], while vegetables and 
fruits that are rich in potassium ought be increased. [44] Intake of fluids should be increased (>2 L 
per day). Various studies have been suggested that diets including fruits and greater intake of 
vegetables play a role in the prevention of kidney stones. [45] 
 
1.4.2. Drug treatment 
The following agents may be applied to thiazide diuretics, allopurinol, and potassium citrate. [37, 46] 
 
1.4.3. Other therapeutic approaches 
Unnatural risk factors for urinary stones such as infection should be identified and treated with 
appropriate antibiotics. Tests for secondary causes of nephrolithiasis, like cystinuria and 
hyperoxaluria, [37]   should be performed. 
1.5. Use of citrate 
Citrate, whose structure resembles that of hydroxycitric acid (HCA) except for the presence of an 
additional OH group on the second carbon atom in HCA is shown in Figure 1.2. 
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  Figure 1.2. Structures for hydroxycitric acid and citric acid. 
  
 
In vitro studies have shown that citrate prevents spontaneous nucleation of calcium oxalate and 
obstructs growth and agglomeration of preformed calcium oxalate crystals. [46, 47] Citrate has also 
been shown to be a potent inhibitor of the calcium phosphate crystals. [48] 
Metastable supersaturation (MSL) is the condition in which the concentrations of solutes may 
significantly exceed their solubility. The mechanism by which inhibitor stone formers maintain 
supersaturation without precipitation of these salts is thought to be a result of crystal inhibitors. [49] 
These inhibitors could be small organic molecules like citrate or larger macromolecules or ions 
which bind to the crystal surface thereby affecting crystal growth. [49] [8] [50] 
 Citrate forms a complex with calcium in urine, thereby directly reducing the saturation of calcium 
stone-forming salts. It is also an inhibitor of crystallization. [51] Coe et al. [52] reported that 
compounds of more substantial molecular weight, such as acidic glycoproteins, were the principal 
inhibitors of calcium oxalate stone formation. However, studies by Pak et al. [53] have suggested 
that citrate is also an inhibitor that increases the "permissible increment" of oxalate, such that 
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greater amounts of oxalate may be present in whole urine before spontaneous precipitation occurs. 
[54] 
 Citrate may be an altering factor for both calcium phosphate and calcium oxalate monohydrate              
crystallisation. [4] 
Alkaline citrates have gained widespread importance in the remedy of kidney stones as these 
elevate urine pH as well as inhibit CaOx and calcium phosphate crystallization. [55]       pH is very  
important as citrate excretion decreases with decreasing pH.   Also the pKa of citrate means that, 
as the urine becomes more acidic, [citrate]3- is converted to [citrate H]2-, which will affect the 
supersaturation of [citrate]3- salts. An increase in pH would have the opposite effect. [56, 57][58][59] 
 
1.6. Hydroxycitric acid 
Hydroxycitric acid (HCA) is one of the principal acids found in the fruit rind of several trees of the 
Garcinia family. [60, 61]   One of these is Malabar tamarind, which is found in Southeast Asia. [62] 
The pulp and rind of the fruit are used for therapeutic purposes, as they contain the most amounts 
of HCA. The dried fruits contain nearly 25% HCA. HCA is isolated as the acid or as one of its 
salts. It can also be isolated in its lactone form. Natural tamarind extracts are presently marketed 
as the calcium or potassium salts of HCA. [67] 
HCA has been added to a number of pharmaceuticals used to treat lipid abnormalities and heart 
disease. [63-66]   It has been advocated to increase stamina and has been used for weight loss. HCA 
consist from two asymmetric centers, and two pairs of diastereoisomers making four dissimilar 
isomers (Figures 1.3). [67, 68] 




                                 
   Figure 1.3. Isomer structures for hydroxycitric acid. 
 
Since the discovery of HCA, its effects and bioactivities have been studied extensively. HCA is an important 
medicinal component with several health benefits in traditional Ayurveda medicine, and ailments such as 
rheumatism and bowel illnesses have been treated with a fruit rind decoction .[62,69-71]  The rind is also used to 
treat certain mouth sicknesses in cattle.  [62] 
HCA is also useful as a strong inhibitor of ATP citrate lyase. The reaction of citrate is: 
                 Citrate + ATP + CoA → acetyl - CoA + ADP + Pi + oxaloacetate  
(ATP, adenosine triphosphate; CoA, co-enzyme A; ADP, adenosine diphosphate) 
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This restricts the formation of acetyl-CoA units. [72] Animal studies have also shown that HCA 
blocks fatty acid synthesis, lipogenesis, food intake,[67] and leads to weight loss.[62, 73] Soni et al. 
reported that in more than 10 years, almost 5 billion dosages of single HCA supplement had been 
sold without any bad side- effects being noted. [74] 
Hydroxycitric acid is not a normal component find in human urine. However, studies have shown 
that orally ingested hydroxycitrate is excreted in the urine, making it potentially a very good 
candidate as a stone therapeutic. [75] 
Various studies of HCA in humans have reported HCA to be well tolerated, with no important 
dangerous side- effects. [74]   Given its molecular similarity to citrate and since it is well-tolerated, 
HCA is theoretically, a viable alternative to citrate as a kidney stone inhibitor. [75] 
HCA is a potent inhibitor of CaOx monohydrate (COM) crystal formation. [52] Cody et al. [76] 
reported that at least two carboxylic acid groups are required for inhibitors to reduce the rate of 
COM crystallisation effectively. Thus, hypothetically HCA may be used instead of potassium 
citrate for the prevention of urinary stones. [77] 
 
1.7. Role of HCA in kidney stones 
HCA is more effective than citrate in counteracting the increased risk of calcium phosphate 
crystallisation associated with increased pH. [78]     Increasing concentrations of HCA lead to a 
maximum of 60% inhibition of calcium oxalate monohydrate (COM) crystallization. [81] This net 
effect reflects the decrease of crystal growth rate as well as the potential inhibition of COM 
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nucleation. [77]   Previous studies of HCA revealed it to be a strong inhibitor of COM crystal 
growth [82] as well as preventing crystal aggregation. [34] In 2019 Kim et al. [75] showed that HCA 
could melt crystal surfaces in supersaturated media (supersaturation ratio S = 4). This was the first 
observation of crystal dissolution in concentrated CaOx solutions. The formula of HCA highlights 
how a small change in molecular structure may markedly alter the influence of a compound on 
crystal growth. [77] [79] [80] 
1.8. Aim 
      The aim of the present research was to establish whether hydroxy citrate affects and/or inhibits 
calcium oxalate crystallisation, and, if so, the extent to which it achieves this relative to citrate. 
 
  1.9. Objectives 
1. To measure the equilibrium constants of HCA with H+, Ca2+, Mg+ and Zn+ using glass 
electrode potentiometry, so that thermodynamic calculations of speciation and supersaturation 
can be performed using these constants. 
2. To determine the structure of metal-ligand complexes using 1H-nuclear magnetic resonance 
(NMR) spectroscopy. 
3. To model the influence of HCA on the speciation of urinary salts in artificial urine (AU) using 
the software program JESS. [83] 
4. To calculate the theoretical supersaturation of stone-forming salts in AU as a function of HCA 
concentrations. 
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5. To experimentally determine the metasable limit (MSL) of CaOx in artificial urine (AU) 
with/without HCA, in order to empirically test the predictions of the theoretical modelling in 
this system. 
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                        2. Potentiometry 
2. 1. Introduction 
Several studies have shown that HCA inhibits the crystallisation of Ca salts in vitro at low 
concentrations. [1, 2]   The thermodynamic role for HCA as a Ca chelator which decreases the 
supersaturation of Ca-containing salts in the urine, has not been previously modelled-perhaps 
because of uncertainty regarding the nature of [Ca(HCA)]- complexes and a lack of reliable 
thermodynamic data under physiological conditions of urinary pH and ionic strength. 
Determining formation constants [8] via potentiometry under these conditions would allow the 
modeling of HCA’s effects on Ca salt supersaturation in urine and may provide insights into the 
clinical relevance of this mechanism. 
Potentiometry is one of the methods used to investigate chemical interactions between acids and 
bases [3, 4] [9] in aqueous solutions. [5, 6] The glass electrode is one of the most reliable sensors 
currently available. [7] 
In the study described in this chapter, potentiometry was used to investigate interactions between 
the ligand HCA (C6H8O8) with H
+ and divalent metal ions, Ca2+, Mg2+, and Zn2+. 
2.1.1. Theory 
The theory of stability constants was described in previous studies [10-13], and a generalized 
formation constant equation (2.1) is shown here 




L + H ↔LH                                                       (2.1) 
 
where L is the ligand, H is a proton, and LH is the protonated ligand. 
 




                                                           (2.2)                                                                              
{LH} is the activity of the single protonated ligand, {L} is the activity of the free 
ligand and {H} is the activity of the proton. 




                                                                 (2.3)                               
where TKL is the concentration equilibrium constant.  
There are three stepwise protonation constants for the ligand of study, hydroxycitrat
L + H↔ LH             TKL1 = 
[𝐋𝐇]
[𝐋][𝐇]
                                  (2.4)
LH + H↔ LH2              TKL2 = 
[𝑳𝑯𝟐]
[𝐋𝐇][𝐇]
                                (2.5)      
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LH2 + H↔ LH3        TKL3 = 
[𝑳𝑯𝟑]
[𝑳𝑯𝟐][𝐇]
                           (2.6) 
 
Further, the following applies for a ligand with n protonation constants: 
 




                   (2.7)      
 
 
Furthermore, the stepwise formation/stability constants (overall formation constant) 𝛽 can be 
expressed as: 
 
L +H ↔ LH                    𝛽𝐿1 = 𝐾𝐿1  =
[𝐿𝐻]
[𝐿][𝐻]
                    (2.8) 
 
LH + H ↔ LH2           𝛽𝐿2 = 𝐾𝐿2  =𝐾𝐿1𝐾𝐿2=
[𝐿𝐻2]
[𝐿][𝐻2]
          (2.9) 
 
In a reaction between a ligand L with a metal M to give a complex ML, the stepwise stability 
constants can be expressed as: 
M + L ↔ ML                  K ML =  
[ML]
[M][L]
                                (2. 10) 
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ML + L  ↔  ML2            KML2   =  
[𝑀𝐿2]
[ML][L]
                                         (2.11) 
  
MLn-1 + L ↔MLn         𝐾𝑀𝐿𝑛 = 
[𝑀𝐿𝑛]
[𝑀𝐿𝑛−1][L]
                                            (2. 12)                      
Consequently: 
 
In the reaction between the proton and the metal ion for the ligand given by equation 2.13. 
 
MLn-1 + LH ↔ MLn + H      𝐾𝐿𝑀𝑛 = 
{𝑀𝐿𝑛}{H}
{MLn−1}{LH}
                  (2.13) 
The reaction of metal M with a ligand can be expressed as: 
M + L ↔ ML           𝐾ML1 = 
[ML]
[M][L]
                                   (2.14)     
ML + L  ↔  ML2      ML1KML2 = 
[ML2]
[ML][L]
                              (2.15) 
 ML2 + L ↔ML3    ML1ML2ML3    =  
[ML3]
[ML2[L]
                 (2.16)
The formation constant (β) of the protonated complex can be expressed as: 
 
 pM + qL + rH ↔   Mp Lq Hr                                                 (2.17) 
 
where p indicates the coefficient of the metal, q is the stoichiometric coefficient of the ligand, and 
r is the stoichiometric coefficient of the proton. 





The formation constant β can be expressed as: 
 
βq p r  =      
𝑀𝑝 𝐿𝑞 𝐻𝑟
[𝑀]𝑝[𝐿]𝑞[ 𝐻]𝑟
                                       (2.18)  
 
 
The concentrations from each titration point can be determined and at point , the concentration is 
expressed as: 
 
[Mp Lq Hr] =   βpqr [M]
𝑝 [L]𝑞 [H]𝑟            (2.19)       
                         
Furthermore, the total concentration of the metal ion TM at point  = 𝑇𝑀 is expressed as: 
 





r        
N
i=1
  (2.20)   
 
 




The total concentration of the ligand TL at point  = 𝑇𝐿 can be expressed as: 





r        
N
i=1
        (2.21) 
 
 
The total concentration of the proton TH at point  =  TH can be expressed as: 
 







r                  (2.22) 
 
If the coefficient of proton r = 1, the complex is protonated. If r  ˂ 0, the ligand has lost all protons, 
the complex is deprotonated, and/or a hydroxyl group (OH) has been added to the complex. [14- 17]  
M L is the mononuclear complex that is not protonated, and r = 0 indicates that no hydroxyl  
group is attached to the complex. MLH refers to a complex with one proton (protonation), and 
MLH2 indicates that the complex has two protons. 
The stability constant of a reaction depends on the temperature and this temperature dependence is 







             or     
𝑑𝐼𝑛
𝑑1 𝑇⁄
  = 
−∆H°
R
                             (2.23)                                                  





where ∆ Ho is the standard enthalpy change of the reaction (expressed in J  mol-1), T is the 
absolute temperature in , and R is the universal gas constant in  J  -1  mol-1. 
 
2.1.2. Instrumentation 
The electrode cell is the centre of any potentiometric investigation. A typical cell for pH glass 
electrode potentiometry comprises a reference electrode (Ere), salt bridge (Ej), and analysis 
solution/glass electrode (Eg). Eref has a known potential and maintains a constant potential   
regardless of the composition of the analyte solution [18]. The observed potential can be expressed 
as: 
 
 cell   =   re +  j +  g                              (2.24)  
 
where Ej is the liquid junction potential dependent on the solution concentration. 
Since the potential of the glass electrode, Eg, changes with the concentration of  the analyte 
solution  
E cell can be written as: 
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 In [H]                     (2.25)     
 
Considering  ∅g is the standard electrode potential and [H] is the concentration of hydrogen ions, 




{H}= H [H]                                                           (2.26) 
 
where is H the activity coefficient of the hydrogen ion and [H] is the concentration of the 
hydrogen ion. 
 





2                                                        (2.27) 
 
where Ci is the concentration of the ionic species, and Zi  is the charge of the ion. 
 





 In [H]can be rewritten 
as: 




    cell =   const + 
RT
F
 In [H+]                                   (2.28)  
Moreover, the glass electrode potential depends on temperature, and the relationship between these 
two factors varies with the hydrogen ion activity, which can be expressed in terms of the slope 
factor S: 
  S = 
2.3𝑅𝑇
𝐹
                                                                  (2.29)  
Substituting S into equation (2.28) yields the following:                                                   
 cell =   constant  + S log [H
+]                          (2.30)  
Calibration the system means determining both E constant and S. 
2.2. Methods  
 2.2.1. Materials 
All chemicals, materials and reagents were commercially available at analytical grade and were 
used without any more purification. Sodium hydroxide and the hydrochloric acid solutions 
(0.01M) were prepared from Merck ampoules (1.09959-Trisol). The ligand, HCA, (C6H8O8) was 
salt from Finetech Industry Limited, web : www.finetechnology-ind.com ,and was 96% purity.  
The concentration of metal ions was measured via ethylenediaminetetraacetic acid (EDTA) 
titration. [20] 
2.2.1. Solution preparation 
All potentiometric titration were performed under an inert atmosphere of purified nitrogen at a 
constant ionic of strength of 0.15 mol∙dm-3 NaCl at 25 °C. All solutions were prepared using 
boiled MilliQ water to avoid carbon dioxide contamination. 




A hydrochloric acid solution (0.01 M) was prepared and standardized against sodium hydroxide 
solution (0.1 M) which itself was standardised versus potassium hydrogen phthalate (KHP) using  
the Gran plot analysis method. [19] The ligand (HCA) solution (0.01 M) was prepared by dissolving 
0.322 g HCA (the ligand form was the potassium salt) into standardized hydrochloric acid (0.03 
M). All ionic solutions were of 0.15 M ionic strength with (Cl-) Na+ as the background  
electrolyte. All metal solutions (0.01 M) were prepared by dissolving CaCl2, MgCl2.6H2O, and 
ZnCl2 (Merck) in boiled, distilled water and adding NaCl (0.12 M) to ensure a constant ionic  
strength of 0.15 mol∙dm3. These solutions were standardized against EDTA. [20] All titrations were    
performed in triplicate. 
 
2.2.2. Potentiometric measurements 
All potentiometric titrations were carried out at a constant temperature of 25 °C and constant ionic strength 
of 0.15 mol∙dm-3 (NaCl).  The slope of the glass electrode was determined using three different buffer 
solutions at pH 4, 7, and 9.  
The value of the Nernstian slope varied from 407.76 to 410.88 mV over a pH range of 2 to 12. The 
intercept, Constant, was determined from strong acid (HCL)-strong base (NaOH) titrations. These titrations 
were also used to calculate pw, which was found to be 13.56 for ligand titrations. The metal to ligand 
molar ratios varied between 1:1 and 1:2 metal ion/ligand system was then titrated with standard solutions of 
NaOH (0.1M). 
     
35 
 
Potentiometric data were analyzed using an equilibrium simulation titration analysis (ESTA) 
software. [21] These data were used to forecast metal-ligand binding to produce models and 
determine the distribution of species in solution. The measurements were carried out using glass 









                         Figure 2.1. Glass electrode 
1. sensing part of electrode. 
2 .sometimes the electrode contains a small amount of AgCl precipitate inside the glass electrode 
3 .internal solution, usually 0.1M HCl for pH electrodes 
4. internal electrode, usually silver chloride electrode or calomel electrode 
5. body of electrode, made from non-conductive glass or plastic. 
6. reference electrode, usually the same type as 4 
7. junction with studied solution.[42] 





2.2.4. Data handling and calculations 
The potentiometric data were analyzed using ESTA [14], a program that analyses potentiometric 
titration data and simulates the equilibrium distributions of chemical species. [22] ESTA has two 
program modules: ESTAl, a simulation module that can determine single values on a point-by- 
point basis for any titration parameter, and ESTA2, an optimization module that can determine the 
best values of the stability constants based on a least-square procedure over a whole system of 
titrations.[23] 
In this study, three tasks from ESTA: Z-bar, Q-bar, and OBJE were employed. The Z-bar task uses 
the mass balance equation and distinguishes the system on a point-by-point basis. Furthermore, 
this task plots the ZH-bar curve for the protonation of the ligand and the ZM-bar function curve for 
the complex formation titrations .[24] The ZH-bar function is plotted against pH and allows the 
estimation of pKa values. 
 ZH-bar is expressed as: 
 
 ZH-bar =   
𝑇𝐻−[𝐻+𝑂𝐻]
𝑇𝐿𝑖𝑔
                                                          (2.31) 
 
where TH is the total concentration of hydronium ions, TLig is the total concentration of the ligand H 
is the concentration of the hydronium ion, OH is the concentration of the hydroxide ion . It is 
possible to estimate pa values from the half ZH-bar values. 




The function of metal-ligand ZM-bar can be expressed as: 
 
ZM-bar = (TL−[L](1+∑nβLHnH
n)/TM                    (2.32) 
where 𝑇𝐿 means total concentration of the ligand, 𝑇𝑀 is the total concentration of the metal, and 
[L] is the free ligand concentration,βLHn is the formation constant of the protonated ligand with n 
protons 
The ZM-bar function is strictly only defined for simple stepwise complexation, where it rises 
monotonically to 1, 2 etc, as ML, ML2, ML3 are formed. Deviations from this stepwise behaviour 
are indicative of the formation of non-simple complexes. Thus, if MLH is one of the species in 
solution, the curve will split at high pL. The bending of the plots indicates the formation of 
hydroxo species. From the ZM-bar graphs, the model of Zn(II)/ligand species Figure 2.10 shows 
that the formation of MLH-1 species begins to form at very low pH’s, the curve fans back. 
ESTA can also be used to calculate Z-bar residual: 
Z-bar residual = Z
o-bar - Z
C- bar                                       (2.33) 
where Zo-bar is the observed Z-bar, and Z
C-bar is the calculated Z-bar. A low Z-bar residual indicates a 
strong agreement between the observed and calculated Z-bar curves. If a ligand has two dissociable 
protons, ZH-bar levels off at two. 
The second ESTA task, Q-bar, reveals how many protons have been released upon complexation 
with a metal ion. 
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N-bar could be defined as the number of protons in the ligand before complexation. Q-bar is 
expressed as: 
 
   QM-bar = 
T∗H−TH
TM
                                                 (2.34) 
where 𝑇𝐻 is the total proton concentration and 𝑇∗𝐻 is the total concentration of protons in the 
system calculated at the observed pH in the absence of metal ion, or  when no complexation took 
place, i.e. 
 





The mass balance equations for 𝑇∗𝐻 and 𝑇𝐿 are written as: 
 
T∗H = H-OH +∑ r
Nj
j=1  {M p L q H r}                                    (2.35) 
TL= L+OH+∑ q
Nj
j=1 {Mp Lq Hr}                                     (2.36) 
 
where the Nj refers to  the total number of titration points. 
ESTA plots QM-bar and n-bar on the same graph against pH. 
The formation function for a ligand, n-bar, can be expressed as:  







r                                                                      (2.37) 
The average number of dissociable protons in a complex can be expressed as: 
  
 
F = qn bar – Q barp                                                                  (2.38)  
where p is the potentiometric coefficient of the metal, and q is the potentiometric coefficient of the ligand. 
n-bar is the average number of protons which would be bound to the ligand in the absence of metal 
complexation. 
The agreement between the experimental and theoretical graphs indicates the validity of the 
chemical model. 
The third task, OBJE, [25] [26] was used to optimise the titration parameters and equilibrium 
constants. The Gauss-Newton method is used to minimise the objective function Uobj, which is 
expressed as: 










 2     (2.39)  
 
where N is the total number of experimental titration points, np is the total number of parameters    
optimised, ne is the total number of electrodes, Wnq is the weight of the q
th  residual at the 𝑌𝑛𝑞
𝑜𝑏𝑠 
titration, 𝑌𝑛𝑞
𝑐𝑎𝑙𝑐  is the calculated variable of the q
th
  the residual at the nth  titration point, and   
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is the observed variable of the qth residual at the nth titration point. 
OBJE also calculates the Hamilton factor 𝑅𝐹
𝐻to ensure the model is accurate. 𝑅𝐹




∑ n−1  e ∑(Wnq )(Ynq
obs)2
)1/2                                                                     (2.40) 
where the R-factor depends on random errors and the number of variables optimised. R
H is 
determined according to value-based variables, and RHLim can be expressed as: 
 
RLim
H  = (
N
∑ n−1  e ∑(Wnq )(Ynq
obs)2
) 1/2                                               (2.41) 
 




All experiments were performed using NaCl as the background electrolyte, at a stable of 
temperature of 25 °C, and an ionic strength of 0.15 mol  dm-3 under an atmosphere of purified 
nitrogen. The electrode slope varied from 56.30 to 57.91, pW was -13.56, and E
0 range between 
410.88 to 407.76 mV. 
 
2.3.1. HCA protonation 
  The protonation constants for HCA are listed in Table 2.1. 
The ZH-bar function is shown in Figure 2.2, with the blue signs representing the experimental data 
points while the red line is calculated based on the model given in Table 2. 1. A bove pH 7, 





ZH-bar is 0, and the ligand is fully deprotonated. Below pH 7, ZH-bar rises, and ligand protonation 
starts. At pH 4.6, ZH-bar ~ 1, indicating that one proton has been added to the ligand. From pH 3.7 
to 2.4, ZH-bar ~ 2.55, which indicates three protons are being added to HCA, The addition of the 
3rd proton is not complete and will only happen below pH 2. No distinct steps (plateau regions) 


































Table 2.1. Stability constants (logβpqr) for hydroxycitric acid (HCA) βpqr = [MpLqHr]/[M]p 
[L]q[H]r, I = 0.15 mol  dm





 its Hamilton R-factor limit. 
 
 





The analysis of the data gave the model shown in Table 2.1. The excellent agreement between the 
experimental data points and curves calculated based on the model given in Table 2.1, the low 
standard deviations, and the fact that RHf  < R
H
Lim indicates the validity of these results.






 nt (np) 
p q r  









0 1 2 9.43 0.004 
0 1 3 12.20 0.009 
     
43 
 
       
The HCA protonation speciation is shown in Figure 2.3 as a function of pH. Between pH 3.78 
and pH 7.54, the predominant species is L. At pH 5.15, LH was most common, followed by LH2 




                                 







Figure 2.3. Speciation curve for hydroxycitric acid (HCA). 
 
 A previous study on citric acid protonation revealed the following pKa values:  pKa1 = 5.83, 
pKa2 = 4.44, and pKa3  = 3.11. 
[28] However, the measurement conditions, including pH, 
temperature, ionic strength, among others, varied, and the agreement between the various 
results, were poor. [29] The log exp values listed in Table 2.2. were compared to the log lit 













L LH LH2 LH3
















2.3.2. Complex formation titrations 
As metal ions are present with the ligand, the number of hydrogen ions set free by complex 
formation is different from titrations of the ligand on its own.[31] The equilibrium constants  
(logβpqr) for the 1:1 , 1:2 and 1:3 the metal-ligand complexes were calculated using the ESTA 
suite of programs and used to determine ZM-bar, QM-bar 






p q r 
logβpqr 𝐑𝐟
𝐇 𝐑𝐋𝐢𝐦
𝐇  nt (np) log exp log lit 






5.47  5.64 
0 1   2 9.43 4.51 4.29 
0 1   3 12.200 3.32 3.41 




2.3.2.1. Ca (II)-HCA complexation 
Ca-HCA complex formation is shown in Figure 2.4. At the titration start (pH 2.7), the ZM-bar is 
approximately 0.02 (greater than 0), indicating that complexation has already started. The ZM-bar 
curves are not superimposable at dissimilar metal: ligand ratios [1:1, 1:2 and 1:3 metal: ligand 
ratio] indicating that protonated species are forming. Table 2.3 lists the model calculated for this 
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Table 2.3. Stability constants (logβpqr) for Ca
2+ and hydroxycitric acid (HCA) complexes. 
βpqr = [Mp Lq Hr]/[M]
p [L]q [H]
r ,T = 25 ºC, I = 0.15 mol  dm-3 (NaCl), St. dev, standard deviation in 
logβpqr, Rf
H
, Hamilton R-factor  and Rlim
H









Model  logβpqr St. dev 𝐑𝐟
𝐇 𝐑𝐋𝐢𝐦
𝐇  nt (np) 
p q r  








6 (249) 1 1 1 8.44 0.01 
1 1 0 3.93 0.01 





The QM-bar function is plotted in Figure 2.5. The n-bar function indicates the number of 
dissociable protons on the ligand at each pH in the absence of metal complexation. QM-bar is the 
total number of protons released by the ligand due complexation. Thus, the difference in these two 
curves indicates the stoichiometry of the species formed. At pH 3, the QM-bar curve is > 0, 
indicating that complexation has already commenced. The QM -bar increases steadily, and MLH2, 
MLH species are evident between pH 3.24 and 4.5. Between pH 5.35 and 6.21, QM -bar 
corresponds with n-bar, indicating no more complexation takes place over this pH range. There is 









   





















The species distribution for the Ca(II)-HCA system is shown in Figure 2.6. ML is the 
predominant metal complex between pH 3.2 and 7.87 and reaches 99.37%. Between pH 2.15 and 
6.22, MLH is most common, and this species reaches 61.50%, whereas MLH2 forms 58.65% of 










Figure 2.6. Speciation curve for Ca2+ with hydroxycitric acid (HCA). 
    
   The stability constants are summarized in Table 2.4. There is general agreement between the 
experimental results, and the literature for citric acid with calcium. [35] Also the protonation 
constants of HCA obtained in the present study were comparable to those reported in the literature 
[30], thus lending confidence to our results.  
The formation constants of HCA complexes obtained in the present study were used to model Ca-
HCA speciation in urine using the program JESS .[36] 






Table 2.4.  Literature stability constants of citric acid with calcium and experimental stability constants of 















p q r 
log βpqr 𝐑𝐟
𝐇 𝐑𝐋𝐢𝐦
𝐇  nt (np) log exp log lit 








1 1  1 8.44 4.51 4.25 
1 1   2 11.76 3.32 3.36 




2.3.2.2. Mg (II)-HCA complexation 
ZM- bar curve of the Mg(II)-HCA complexes are shown in Figure 2.7. The ZM-bar curve levels 
off at approximately 0.57 indicating that the ML species is not the only species present in 
solution. There is a strong agreement between the experimental and theoretical curves. 
The log βpqr value for the Mg (II)-HCA complexes are listed in Table 2.5. The standard deviation 












                Figure.2.7. ZM-bar for Mg



















Table 2.5. Stability constants (logβ p q r) for Mg
2+ and hydroxycitric acid (HCA) complexes. 
βpqr = [Mp Lq Hr]/[M]
p[L]q[H]r, I = 0.15 mol  dm-3 (NaCl), T = 25 ºC, St.dev, standard deviation in 
   log βpqr; Rf
H, Hamilton R-factor; Rlim













nt (np) p q r 








3 (133) 1 1 1 7.97 0.01 





The QM-bar for the Mg(II)/HCA titration is shown in Figure 2.8. The n-bar curve levels off at 
approximately 2.5, which indicates the ligand has three dissociable protons. The QM-bar curve 
begins at values greater than 0, indicating that complexation has already started, and between pH 

















           Figure 2.8. QM-bar for Mg
2+ and hydroxycitric acid (HCA). 
 
 
The distribution curves for the Mg(II)-HCA complexes are shown in Figure 2.9. The 
predominant species was ML produced from pH 3.35, with MLH and MLH2 present at 59.5% 









































Figure 2.9. Speciation diagram for Mg2+ and hydroxycitric acid (HCA). 
 
The stability constants of the Mg(II)-HCA complexes were compared with those of Mg(II)-citric acid. [37] 
Table 2.6 showed that the log  values did not differ significantly from the literature values. 
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Table 2.6. Literature stability constants of citric acid with magnesium and experimental stability constants 














2.3.2.3. Zn (II)-hydroxycitric acid complexation 
The stability constants (logβpqr) for the Zn(II)-HCA complexes were calculated using the ESTA 
suite of programs and used to calculate the model ZM-bar, QM-bar, and the species distribution 
functions. The ZM-bar curve for the Zn(II)-HCA complexes (Figure 2.10) levels off at ~0.8. This 
indicates that the formation of the ML species.  Since the ZM-bar function deviates from its 
normal shape when varying the metal to ligand ratio (1:2, 1:3), the formation of other species in 
solution is indicated. In this case protonated and hydroxy species are suggested. 
Model 
p q r 
logβpqr 𝐑𝐟
𝐇 𝐑𝐋𝐢𝐦
𝐇  nt (np) log 
Kexp 
logKlit 








1 1  1 7.97 4.69 4.09 
1 1   2 11.55 3.58 3.43 














             Figure 2.10. ZM-bar for Zn 
2+ and hydroxycitric acid (HCA). 
 
 
Results of the potentiometric data analysis using the ESTA suite [38] of programs are listed in Table 
2.7 and show low standard deviations and Hamilton R-factors. This indicates the accuracy of the 
model. 
Table 2.7. Stability constants (log βpqr ) for the Zn 
2+ hydroxycitric acid (HCA) complexes. 





r, I = 0.15 mol  dm-3 (NaCl), T = 25 ºC,St. dev, standard deviation 
in logβpqr; Rf
H, Hamilton R-factor  RLim






























nt (np) p q r 















1 1 1 8.83 0.02 
1 1 0 4.59 0.04 
1 1 -1 -3.01 0.08 
 
The QM-bar function (Figure 2.11) is > 0 at pH 2.3, indicating complex formation, and the 










              Figure 2.11. QM-bar for Zn


















The speciation of Zn(II)-HCA is shown in Figure 2.12 and indicates the start of complexation at pH 2.15.  

























The focus of this chapter was the measurement of the stability constants of HCA complexes with the bivalent 
metal ions Ca2+, Mg2+, and Zn2+. The present investigator used the complexation of HCA with these divalent 
metals as a proxy for that of citric acid, as citric acid is identical except for an OH-group on the second carbon 
atom. Citrate anions are well known to form complexes with alkali mineral cations,
[39]
 which is reflected in 
the different apparent values for logβ for citrate with metal. In 1975, Field et al. studied 
[31] 
metal complexes 
in solutions of citric acid with Ca, Mg, and Zn. The stability constants are MLH and ML are 8.02, 3.5 
respectively. The values for ML species for calcium citrate complexes concur with those reported by Campi 
et al. 
[29]
 and Pearce, but are greater than those reported by Li et al.
[40] The values for MLH species were in 
agreement with Pearce’s but were higher than those reported by Campi et al. This discrepancy with regard to 
MLH and MLH2 species is related to the inability to characterise MLH2 as a discrete species. 
[31] The results 
of the present study show three species ML, MLH, and MLH2. The stability constants for Ca(II)-HCA (ML 
= 3.93, MLH = 4.51, and MLH2 = 3.32) are higher than the stability constant of citric acid reported by Field. 
et al. [31]  The percentage Ca uncomplexed in the Ca(II)-HCA complex is 60.27% in the present study, and 
50.7% in the Ca(II)-citric acid complex reported by Field et al. [31] A summary of the results of stability 
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For the Mg-citrate species, Field et al. 
[31] reported logβ111 = 7.66 and logβ101 = 3.38, which is in 
agreement with the values reported by Campi et al [41] and Pearce et al.[29]  Covington et al. in 
2009[37] reported different stability constants: logβ110 = 3.31, logβ111 = 7.40, and logβ112 = 10.83.  
These values are analogous to those of the present study (logβ110 = 3.28, logβ111 = 7.97, and logβ112 = 
11.55). A summary of the results of stability constant of Mg(II)-HCA compression with magnesium citrate 
is shown in Table 2.9 for quick and easy reference by the reader. 
       Table 2.9. Summary of stability constant for magnesium citrates and HCA with magnesium. 
 Magnesium Magnesium Reference 
logβ111 logβ101  
Citrate 7.66 3.38  [31] 
 7.40 3.31 [37] 
HCA 7.97 3.28  
 
 Calcium 
logβ111    logβ101 
Citrate 8.2 3.50 
HCA  8.44 3.93 




The stability constant for the Zn(II)-citrate complexes reported by Field et al. [31]  namely logβ101 
= 5.10, log β111 = 8.98,  concur with those reported by Campi et al.
[41]  The results in the present 
study differ logβ101 = 4.5, logβ111 = 4.24, logβ121= 3.6, and logβ11-1 = -3.01. Furthermore, the 
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                               Chapter Three 





 3. 1H-NMR spectroscopy 
 3.1 Introduction 
1H-nuclear magnetic resonance (NMR) spectroscopy is a technique used to investigate a 
compound’s unique structure. [1-3]   The technique is flexible, has many applications, and provides 
information regarding chemical bonding, electronic structure, and local site dynamics. [4, 5] 
In recent years, the implementation of NMR has been extended to medicine [6] through magnetic 
 resonance imaging (MRI) [7] and also biology. [6] 
In this study, 1H-NMR was used to gain insight into the site of metal coordination upon 
complexation of HCA with Ca2+, Mg2+, and Zn2+ ions. [8]   The presence of metal ions is expected 
to cause a shift in the signals arising from protons attached to carbons near the site of 
coordination.  [9, 10] 
 3.2. Experimental 
A solution of 0.01 M HCA was prepared in D2O at 25 ℃. Tert-butanol was added as the internal 
reference, and the pD of the solutions was adjusted using concentrated DCI and NaOD. The 
spectra were recorded at predetermined pH values from pH 2 to 6, and 1H-NMR signal 
broadening and shifting were analysed. [11] 
An Acrison micro pH meter and a Metrohm glass electrode were used to measure pH, and 
corrections were made by using Equation 3.1 described by Popov [12] and Glasoe.[13]  






pH = pD − 0.044                           (3.1) 
 
 
For the metal complexation reactions, the pH values were selected to reflect the maximum concentration of 
a single species according to the species distribution diagrams, and the pH of each solution was monitored 
and kept constant during each experiment. 
Solutions of CaCl2.2H2O, MgCl2.6H2O, and ZnCl2 (0.01 M) were prepared in D2O. These solutions were 
titrated into the 0.01 M HCA solution. 
1H-NMR spectra were recorded on a Bruker DRX600 MHz spectrometer and data processed using the 
software Mestrenova. 
 3.3. Results 
 
            Figure 3.1 shows the proton numbering for HCA, and the 1H-NMR spectra of HCA, as a 
function of pH (pH 2 to 6), are shown in Figure 3.2. 
Between pH 3 and 6, the signals for Ha1, Ha2, and Hb shifted to a lower frequency. This shift 
(in signals) is due to a change in the shielding of the protons as the HCA becomes deprotonated. 

















 Figure 3.1. Structure of hydroxycitric acid (HCA). Proton labels are shown in Figure 3.2. 
  




















Figure 3.2: 1H-NMR spectra of hydroxycitric acid (HCA) as a function of pH. 
Proton chemical shifts were plotted against pH and shown in Figure 3.3. Several authors have 
previously used shifts in chemical shifts with pH to estimate pa. 
[14, 15]
   In the case of HCA, all 
three protons shift at the same time, so these results could not be used to assign protonation sites. 
The fact that all the protons shift at the same time indicates that all sites are being protonated at  




the same time. This means that several microstates, with very similar protonation constants, exist 
simultaneously [16] these possible microstates are shown in Figure 3.4.  Figure 2.2 showed that  
the same phenonium, the protonation steps were not well separated and the formation curves did 







 Figure 3.3. Change in chemical shift of selected hydroxycitric acid (HCA) protons as a   
      function of pH.    







Figure 3.4. The effect of microstates on the pKa values of hydroxycitric acid (HCA). 





At pH 4, unusual signals were observed for Ha1 and Ha2 (see Figure 3.2). As the signals were 
different from those observed at other pH values, this spectrum was repeated on the same day and 
5 days later (Figure 3.5). The results obtained indicate the formation of HCA-lactone. The 














          Figure 3.5. 1H-NMR spectra of hydroxycitric acid (HCA) at pH 4. 





HCA has two asymmetric centers; it has two pairs of diastereoisomers or four different isomers are 
possible, as shown in Figure 3.6. Each of these diastereomers may form a lactone ring. [17, 18] 
Free (-)-HCA is unstable and is usually converted to the (-)-HCA lactone through concentration 
(drying) and evaporation. The configurations of the hydroxycitric acid lactone were determined to 
be (2S,3R)- and (2S,3S). [17, 18] 
 
 
         Figure 3.6. Isomer structures of hydroxycitric acid. 
 
 










   
        
        Figure 3.7. Structure of (2S,3S)- hydroxycitric acid lactone (HCA-lactone). 
 
3.3.1. Ca (II)-HCA complexes 
1H-NMR results for the complexation of HCA with Ca(II) are shown in Figure 3.8. 
According to the potentiometric studies reported, in Chapter 2, complexation starts at pH 1.8, and 
therefore a change in NMR signals was expected at pH 2. At this pH, all peaks shifted to a high 
frequency. This shift indicates that Ca(II) coordinates to HCA. 
 




At pH 4, both HCA and HCA-lactone exist in solution. For HCA, the peaks were slightly shifted 
and broadened. This broadening may indicate that several different structures coexist in solution 
with a rapid exchange between them. For HCA-lactone, the signals Ha1, Ha2 were broadened, 
indicating that the Ca(II) coordinated to the lactone. 
At pH 7, not all the peaks broadened to the same extent. The Hb peak broadened more than that 
of Ha1, and Ha1 broadened more than Ha2. 
The broadening in Hb and Ha1 means complexation between Ca(II) and HCA is occurring. 
From potentiometry studies, at this pH, the ML species is most abundant. The broadened peaks 
indicate that there is an exchange between structures but not at the slow exchange limit, or 
separate signals would be seen for each structure. In fact, two signals can be seen for Hb. 
From the potentiometric study, the metal is not monodentate – the equilibrium constant is too high. 
This means that the metal will bind to several sites at the same time to form five or six-membered 
rings. Four possible structures for [Ca(HCA)]- are shown in Figure 3.9. The intermediate exchange 
between these isomers would result in line broadening. If the central hydroxyl group was 
coordinated, a structure similar to that found for aluminium(III) with citrate would be formed. [19] 






   Figure 3.8. 1H-NMR spectra of hydroxycitric acid (HCA)-Ca(II) complexes in D2O. 


















3.3.2. Mg (II)-HCA complexes 
 
The 1H-NMR spectra of the HCA - Mg(II) complexes at pH 2.8, 3.67, and 9.38 are shown in Figure 
3.10. There is very little difference between the spectra with and without Mg(II). Here it is not 
possible to say anything about the structure of the complexes formed in solution from these results. 
 
 
   Figure 3.10. 1H-NMR spectra of hydroxycitric acid (HCA) -Mg(II) complexes in D2O. 





3.3.3.  Zn(II)-HCA complexes 
 
1H-NMR spectra for the complexation of HCA with Zn(II) are shown in Figure 3.11. 
At pH 3.05, all the peaks a1, a2, and b were broadened, indicating that the Zn(II) was complexing 
to the HCA. The MLH species is assumed to predominate at this pH. 
At pH 4.27, the HCA-lactone was formed. The lactone peaks are shifted relative to their position 
in the absence of Zn(II), and so the present investigator concludes that the metal is coordinated. 
However, the mode of complexation of these species could not be determined. 
At pH 6.67, all peaks shifted to a higher frequency, and peak b is split into two. The dominant 
species at this pH is ML. Once again, there must be an exchange between different structural 
isomers of the complex. 





    Figure 3.11. 1H-NMR titration for complexation of hydroxycitric acid (HCA) with Zn(II) in D2O. 
 
3.4. Discussion 
The spectra were recorded at different pH values at which the maximum concentrations of the 
various species were observed, as deduced from the speciation diagrams. 
For HCA alone, all the protons in 1H-NMR spectra shifted in response to changes in pH. A plot 
showing the chemical shift against pH revealed that when a proton was added, all the signals 
shifted. Thus, these data could not be used to estimate the pKa values of HCA or to assign  





protonation sites to individual pKa’s. HCA has three protonation sites,   whose pKa   values are 
too close to resolve.  In solution, an equilibrium exists between several microstates with a rapid 
exchange between them. 
The results obtained at pH 4 were surprising and showed the reversible formation of a lactone. 
The solution structures of the metal (Ca2+, Mg2+, and Zn2+)-HCA complexes were also 
investigated by using 1H-NMR. The idea was that those protons closest to the coordination site 
would be most affected. On addition of the metal ion, however, all the peaks shifted and/or 
broadened. Shifting of the proton signals is due to the inductive effect of the metal ion. None of 
the metal ions is paramagnetic, and so the broadening must be exchange broadening. That is, 
several different structural isomers of a species must exist in solution, at the same time. Since the 
chemical shifts of the different isomers will be different, rapid or intermediate (on the NMR time-
scale) exchange between them will lead to signal broadening. Thus, the NMR results were 
inconclusive or showed that even for the metal complexes, several microstates co-exist in 
solution. 
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                         Chapter Four 





4. Effect of HCA on chemical speciation and supersaturation 




Chemical speciation is essential in understanding the form of chemicals of interest in natural 
systems. [1] The International Union of Pure and Applied Chemistry (IUPAC) has defined 
speciation as the specific form of a chemical element in reference to its molecular, electronic, or 
nuclear structure. [2] According to IUPAC “speciation” denotes the distribution of an element 
amongst defined chemical species in a system. [2, 3] Chemical speciation is essential for gaining 
insights into the biological availability and possible toxicity of chemical complexes and holds 
significance concerning the potential of biosensors in investigating metal pollution. [4] Chemical 
speciation has caught the notice of many investigators in the fields of risk analysis, dental care, 
total parenteral nutrition, metallurgical operations, and environmental protection. [5, 6] It is, 
therefore, useful to determine the speciation of calcium and other elements, which in turn 
contribute to the supersaturation (SS) of stone-forming salts. As mentioned in Chapter 2, HCA 
contains three carboxy groups and two hydroxyl groups (OH), thus allowing HCA to form 
complexes with Ca in urine.




If calcium is complexed to HCA, less is available for binding to free oxalate (or phosphate). The      
SS of (Ca-phosphate) CaP and (calcium oxalate) CaOx, therefore, is lower, thereby decreasing 
the risk of crystallization of these substances. The extent to which this occurs is contingent on 
the chemical composition of urine. Thus, HCA could, be potentially used as a curative agent 
against the formation of kidney stones, specifically those compose of CaOx and CaP. 
In the present study,the theoretical effect of HCA on the speciation of calcium was modelled by 
using the speciation program JESS. [7, 8]  JESS is extensively used to model metal-ligand 
equilibria in biological systems. This program comprises an extensive database of 
thermodynamic constants for one or multiple binary, tertiary, and quaternary complexes that may 
form at equilibrium. It also takes into account changes in ionic strength and the formation of 
solid phases. The JESS database system provides a powerful and versatile means of storing and 
retrieving thermodynamic data associated with chemical reactions. [7, 8] In recent years, Jess has 




The chemical speciation was evaluated in a solution of chemical composition typical of urine 
(Table 4.1) in the absence of HCA (“control”) and the presence of 1 mM HCA. [15, 16] Previous 
studies by Chung and et al. [30] showed that the concentration of HCA in urine after 
supplementation was 0.7 mM. An elevated concentration of 1 mM HCA was used for modelling  
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in the present study to highlight Ca-HCA interactions. The JESS software set was used to 
calculate the speciation. In order to achieve this, the JESS database was expanded to include the 
thermodynamic binding constants for HCA with H+, Ca2+, and Mg2+, which were determined 
experimentally as part of the current study (Chapter 2). 
Equilibrium constants and species formation are dependent on temperature and ionic strength. [18] 
Accordingly, the temperature for the urine model was set at 37 °C (physiological temperature). 
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Table 4.1. Urinary concentrations used in JESS modelling. 
 






























4.3.1. HCA speciation 
The percentage distribution of each HCA species in urine with 1 mM HCA is shown in Figure 4.1, 
while the percentages and concentrations for each species are provided in Table 4.2. 
At 1 mM concentration, most of the HCA is complexed to Ca in the form of [Ca(HCA)] - (65%). 
The other major species is free HCA-3 (28%). Thus, HCA does affect the speciation of Ca and 

























1.HCA-3 2.[Ca(HCA)]- 3.H(HCA)-2 4.Ca(HCA)H
5.H2(HCA)
- 6.Ca(HCA) H2 7.H3(HCA)
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Table 4.2. Percentage distribution of HCA  species in urine 
 
Species % HCA [HCA] 
mol/L 
HCA-3 28 0.0002786 
[Ca(HCA)]2- 65 0.0006518 
H(HCA)2-        5 5.07-05 
[Ca(HCA)H]-        2 1.86-05 
H2(HCA)
-
        0 3.73-07 
]Ca(HCA)H2]        0 3.89-08 
H3(HCA)         0 1.98-10 




4.3.2. Calcium speciation 
 
The percentage distribution of Ca+2 species in urine and urine containing 1 mM HCA is shown in Figure 













 Figure 4.2. Percentage distribution of calcium species in urine and urine containing 1 mM HCA. 
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Table 4.3. Calcium species in urine and urine containing 1 mM HCA 
 






    mol/l 
(%) 
Ca
+2 0.0008062 41 0.0006038 31 
[Ca(HCA)]- 0.000 0 0.0006518 33 
CaCit- 0.0004915 25 0.0002840 14 
CaSO4 0.0003438 17 0.0002188 11 
CaH(PO4) 0.0001198 6 7.177-5 4 
CaH3(PO4)2 9.212-5 5 5.010-5 3 
CaH2(PO4) 3.745-5 2 2.038-5 1 
CaOX 1.168-5 1 8.378-6 0 
Ca (HCA)-H 0.000 0 1.8566-5 1 
 
As expected, the Ca urinary speciation is significantly affected by 1 mM HCA. There is a 10% 
drop in the free Ca2+ concentration, which affects the concentration of other Ca species. In order 
to see if this change is sufficient to affect the supersaturation of calcium oxalate monohydrate 
(COM) or calcium dihydrogen phosphate (brushite), it is necessary to calculate the relative 
supersaturation of these two solids (see section 4.4). 




4.3.3. Oxalate speciation 
The percentage distribution of oxalate species in urine and urine containing 1 mM HCA is shown 
in Figure 4.3. Percentages and concentrations are listed in Table 4.4. 
On addition of HCA, the free Ox-2 concentration increased. At the same time, the concentration 
of MgOx and CaOx decreased. These decreases mean that less free oxalate has been utilized, 
thereby explaining the increase in [Ox]2-. The decrease in CaOx concentration is understandable 
because free Ca2+ has decreased. The change in MgOx concentration is counter-intuitive, however, 
as the free Mg2+ has increased (see later). This illustrates the interconnectedness of the speciation 
and why it is so difficult to predict. The 4% decrease in MgOx in urine containing 1 mM HCA 









         Figure 4.3. Percentage distribution of oxalate species in urine and urine containing 1mM HCA. 
 




Table 4.4. Oxalate speciation in urine and urine + 1 mM HCA. 
 









-2 5.942E-5 40 6.698-5 45 
NaOx- 2.962-5 20 3.060-5 20 
MgOx 3.564-5 24 2.999-5 20 
CaOx 1.168-5 8 8.378-6 6 
KOx- 1.211-5 8 1.246-5 8 




4.3.4. Phosphate speciation 
The percentage distribution of phosphate species is shown in Figure 4.4. Percentages and 
concentrations are listed in Table 4.5. 
The result showed a decrease in 3% of the species H2PO
4- [species number 1, Figure 4.4] in the 
attendance of 1 mM HCA in urine; this is accompanied by rise in 2% HPO4
-2 which forms upon 
the deprotonation for the former species. 
HPO4
-2 is a precursor to the creation of CaP.[13] Thus, an increase in HPO4
-2 is expected to lead to 
an increase in the supersaturation of CaP salt; however, the opposite happened because the 
upsurge in HPO4
-2 is outweighed by the reduction in Ca +2 (Table 4.3). The same observation has 











                Figure 4.4. Percentage distribution of phosphate species in urine and urine containing 1 mM HCA. 




Table 4.5. Phosphate species in urine and urine containing 1 mM HCA 
 
  





















0.002513 10 0.003046 12 








0.0008055 3 0.0009425 4 
H2KPO4 0.0009876 4 0.0009169 4 
HNa2PO4 0.0002251 1 0.0002058 1 




0.0002107 1 0.0001654 1 




4.3.5. Citrate speciation 
The percentage distribution of citrate species is shown in Figure 4.5. Percentages and 
concentrations are listed in Table 4.6. 
In the presence of HCA in urine, the Cit-3 distribution increased by 5 %. At the same time, 
CaCit- concentration decreased by 10% and CaH2Cit2
-2 by 1%. This is because of the formation 
of [Ca(HCA)]- (Table 4.3, species number 2), which utilises a large amount of Ca+2 and leads to 












     Figure 4.5. Percentage distribution of Cit-3 species in urine and urine containing 1 mM HCA. 
 
  


















Mg(Cit)- 0.0008381 39 0.0009292 43 
CaCit- 0.0004915 23 0.0002840 13 
Cit-3 0.0002861 13 0.0003915 18 




      1 5.961-5               3 




      1 6.784-6              0 
 
 




4.3.6. Magnesium speciation 
The percentage distribution of magnesium is shown in Figure 4.6. Percentages and concentrations 
are listed in Table 4.7. 
The presence of HCA leads to a rise in the concentration of Mg2+ and MgCit-. This increase in 






















Table 4.7. Mg+2 species in urine and urine containing 1 mM HCA 
 









+2 0.001365 42 0.001496 46 
MgCit- 0.0008381 26 0.0009292 29 
MgH3(PO4) 2
-1
 1.434-5         0 1.089-5                  0 
MgH2(PO4) 2
-2
 0.0002107        7 0.0001654                 5 




1.479-5        0 2.980-5                 1 
MgHPO4 0.0002313        7 0.0001943                  6 
 
4.4. Effect of HCA on supersaturation in urine 
Supersaturation refers to the force driving the formation of stones in urine. [19, 20] It is often expressed as 
relative supersaturation (RS). In this study, the influence of varying the concentration of HCA in urine on 
the RS of calcium salts was investigated. 
Kidney stones are made up of different minerals. The most common component is calcium oxalate 
(CaOx), which accounts approximately 70% of all kidney stones. CaOx can be found as the monohydrate 
(crystal name: whewellite) or dihydrate (crystal name: weddellite) forms. [21] It can also be found in 
combination with uric acid or calcium phosphate because calcium oxalate stones typically grow on 
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Randall's plaque on the papillary tip [22] [23] Calcium phosphate is found in about 15% of kidney stones and can be 
present in combination with calcium oxalate or struvite. Because of differences in pH urine at which the two minerals 
precipitate, calcium phosphate is not found mixed with uric acid. The two types of CaP include apatite (sometimes 
reported as carbonate apatite), which is the crystal kind found in bone, or calcium hydrogen phosphate (brushite); the 
frequency of apatite is more than brushite. Calcium phosphate crystals in the urine sediment are typically dark and 
amorphous. [21] 
A kidney stone may form when substances such as calcium, oxalate, or uric acid are present at 
high levels in the urine. [24] Stones may also form if these substances are present at normal levels, 
especially if the amount of urine produced each day is low. [25] Once crystals form, they may 
become anchored in the kidney and gradually increase in size (crystal growth) to form a kidney 
stone. [26] In order for a mineral to precipitate, it must exceed its solubility product. Thus, an 
important parameter used to evaluate the risk of kidney stone formation is the relative 
supersaturation of the salt. In this study, the RS of various salts was calculated by determining 
the saturation index (SI), using the program JESS. [7] 
The SI of different calcium salts as a function of HCA concentration are shown in Figures 4.7 to 
4.9, and data at the various concentrations of HCA vs SI are reported in Appendix from Tables 4.8 
to 4.10. 
Increasing the concentration of HCA decreased the SI of COM, hydroxyapatite, and brushite. At 
an HCA concentration of 0.002 M, the urine was no longer supersaturated in COM. This 2 mM 
HCA is double the amount used in our JESS modelling but is clinically easily achievable. 
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Various trials of HCA in humans have reported HCA to be well tolerated, with no significant 
adverse events. [27-17] 
A much higher concentration of HCA (10 mM) is needed to achieve a SI of 1 for apatite. 
The result in the present study showed that a concentration 1 mM HCA significantly decreases 













































































































It has been reported/suggested that HCA can be used to decrease the risk of CaOx kidney stone 
formation. [ 31] Studies at the University of Houston [17] reported HCA is capable of dissolving COM 
crystals. These in vitro studies established that an increased number of hydroxyl and carboxyl 
groups play a crucial role in specific COM crystal surfaces. 
In 2019, Kim et.al. showed that HCA could melt crystal surfaces in supersaturated media 
(supersaturation ratio S = 4). This study was the first observation of crystal dissolution in a 
concentrated CaOx solution .[31] The study described in the present chapter aimed to investigate 
the theoretical role that HCA may play in controlling the thermodynamic crystallisation of calcium 
stone-forming salts in artificial urine role. 
Speciation calculations showed that at a moderate concentration of 1 mM, HCA significantly 
affects the in vitro speciation of calcium. At this concentration, in ideal urine, 33% of the calcium 
is in the form of [Ca(HCA)]-. A result of this complexation of Ca2+ is that the free calcium 
concentration decreased. Having established that HCA affected calcium speciation, the question 
arises, is this sufficient to change the SI of important kidney stone minerals. Here it has been shown 
that, indeed, HCA decreased the SI of COM and brushite. HCA also reduced the SI of apatite but 
to a lesser extent. 
In conclusion, it has been shown that HCA has a thermodynamic effect on the risk of kidney stone 
formation. However, the possibility exists that it may also affect the kinetics of CaOx crystal 
formation. This is described in the next chapter. 





Table 4.8. Hydroxyapatite log SI and HCA concentrations. 
log SI HCA (mM) 









































































Table 4.9. Brushite log SI and HCA concentrations 
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Table 4.10.  log SI COM vs HCA concentrations. (COM: Calcium oxalate monohydrate) 
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5. In vitro study of the effect of hydroxycitric acid 
(HCA)   on calcium oxalate (CaOx)                  
crystallisation 
5.1. Introduction 
The crystallisation capacity of urine may be used as an estimate of the risk to form kidney stones. [1] 
In vitro crystallisation studies in both artificial urine and real urine remain of fundamental 
importance in kidney stone research. 
 Many different methods have been used to mimic the physiological aspects of the urinary system 
to differentiate between processes of crystallisation, such as nucleation, aggregation, and growth. 
[2, 3]   These methods may be classified in terms of technique, or in terms of supersaturation levels 
in the kidney. [4] 
As previously described in Chapter 4, modelling showed the presence of the [Ca (HCA)] - 
complex led to decreased CaOx concentrations in urine, and concomitant decreases in the 
supersaturation of COM and brushite under physiological conditions. 
In the present study, artificial urine (AU) was prepared according to the method described by 
Walton and et al. [5] 
HCA is not a component of human urine. Primary studies have shown that orally ingested hydroxy 
citrate is secreted in the urine. [6] 




Various trials of HCA in humans have reported HCA to be well tolerated, with no significant 
danger to health. [7] Thus, in the context of the present study, it is an excellent candidate as a 
potential therapeutic agent for crystal and stone formation. 
Regarding its effect on crystallisation, Chung [8] showed that HCA inhibits CaOx crystallisation to 
a greater extent than citric acid. In 2019, Kim et al. reported that HCA could melt crystals 
surfaces in supersaturated media; this was the first observation of crystal dissolution in 
concentrated CaOx solution. [6] 
The purpose of the study described in the present chapter was to determine the effect of HCA on 
the metasable limit (MSL) and total CaOx crystallisation kinetics. 
The objectives of the experiments described in this chapter were to: 
1. measure the CaOx metasable limit (MSL) and CaOx crystallisation kinetics in AU. 
2. measure the CaOx metasable limit (MSL) in AU containing HCA instead of citrate 
3. measure the metasable limit (MSL) in AU containing citrate and HCA at a ratio of 1:1. 
4. measure the metasable limit (MSL) and crystallisation kinetics in AU containing HCA at 
different concentrations and compare these results with that obtained for the control AU 
(zero HCA). 
5.2. Preparation of artificial urine  
Artificial urine (AU) was made according to the method reported by Walton et al. [5] A stock 
solution of AU was prepared from 320 mM NaCl, 50 mM NaH2PO4, 6.52 mM MgCl2, 164.2 mM  




KCl, 4.34 mM K3 citrate, 43.8 mM (NH4)2SO4, and 7.0 mM NH4Cl. and an appropriate volume 
(1000 ml) of distilled water. The pH was adjusted to pH 6 using 5 M NaOH.  
Solutions of 50 mM Na2Ox and 120 mM CaCl2 were prepared separately and filtered. 
Next, 16.7 mL CaCl2 and 3 mL Na2Ox were added to 480.3 mL AU stock solution and diluted to 
a volume of 1000 mL using MilliQ water. The solution was stored at 4℃ for 24 h until it was 
ready to be used. Immediately before use, the solution was heated to 37℃ and filtered. The final 
concentrations of calcium and oxalate were, therefore, 2.0 mM and 0.15 mM, respectively. 
5.3. Measurement of CaOx metastable limits 
The CaOx MSL is a measure of the ability of a solution to resist spontaneous crystallisation of 
CaOx. [9, 10] The protocol described by Ryall was used to determine this parameter in AU. [10] 
In this method, 10 mL samples of AU (x 13) were incubated at 37°C. Each sample was dosed with 
increasing concentrations of Na2Ox to obtain final concentrations of oxalate in the range 0.15 -
1.95 mM. Dosing was performed at 1-minute intervals. 
After an incubation period of 30 min, the absorbance of each sample was measured in a glass 
cuvette at 620 nm. The MSL was determined by plotting the absorbance against Na2Ox 
concentration. 
The concentration at which a sudden increase in absorbance occurred was recorded as the MSL. 
All experiments were repeated three times, and the average CaOx MSL was determined. 
Five MSL experiments were conducted: 




(i) AU (control). 
 
(ii)  AU containing HCA instead of citrate (concentration 4.34 mM). 
 
(iii) AU containing HCA and citrate (1:1) (Concentration HCA = concentration Cit = 2.17 mM). 
 
(iv) AU control + 0.5 mM HCA. 
 
(v) AU control + 1 mM HCA. 
5.3.1.Results 
Experiment (I): AU (Control) 
As a control, the MSL of CaOx was measured in AU. The averaged plot for absorbance vs Na2Ox 
concentration is shown in Figure 5.1. The MSL of 0.75 mM Na2Ox is indicated as the point 
(concentration) at which the absorbance of the solution increases. This is the concentration at 





























































Experiment (II). AU containing HCA instead of citrate 
In this experiment, the concentration of citrate was zero, while that of HCA was 4.34 mM. The 










 Figure 5.2. Mean absorbance as a function of Na2Ox concentration in AU containing     




































Experiment (III). AU containing HCA and citrate (1:1) 
In order to see at what concentration HCA affects CaOx MSL, different concentrations of HCA 
were tried. In this particular experiment, the concentrations of HCA and citrate in the AU were 
each 2.17 mM. The result is shown in Figure 5.3. It can be seen that the CaOx MSL is now 1.20 
mM. This result is intriguing as it demonstrates that HCA alone (experiment #2, MSL 1.35 mM) 
has a stronger effect on the MSL than when it is present in combination with citrate (experiment 





































Experiment (IV). AU control + 0.5 mM HCA 
The result is shown in Figure 5.4. It can be seen that the MSL of AU containing 0.5 mM HCA 













           Figure 5.4. Mean absorbance as a function of Na2Ox concentrations in AU containing 0.5  
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Experiment (V). AU control + 1 mM HCA 











        Figure 5.5. Mean absorbance as a function of Na2Ox concentrations in AU containing 1  



































A summary of the results of the CaOx MSL experiments is shown in Table 5.1 for quick and easy reference 
by the reader. 
Table 5.1. Summary of CaOx MSL values in AU containing various concentrations of Cit and HCA. 
 
Experiments Experiment 1 
Control 
 
[conc Cit = 
4.34 mM, conc 
HCA = 0] 
Experiment 2 
AU– Cit + 
HCA 
 
[conc  Cit  = 0, 
conc HCA = 
4.34 mM] 
Experiment 3 
Cit: HCA: 1:1 
 
[conc Cit = conc 
HCA = 2.17 mM] 
Experiment 4 
Control + 
0.5 mM HCA 
 
[conc Cit = 4.34 
mM, conc HCA 
= 0.5 mM] 
Experiment 5 
Control + 
1.0 mM HCA 
 
[conc   Cit   = 
4.34 mM, 




0.75 1.35 1.20 0.75 1.20 
 
Comparison of experiments 1 and 2 shows that when citrate is replaced by HCA, the CaOx MSL 
increases from 0.75 to 1.35 mM Na2Ox. This means that HCA has a more powerful effect on the 
MSL than citrate. This can be accounted for by the higher value of the thermodynamic binding 
constant for Ca(II)-HCA = 3.93 compared to Ca(II)-Cit = 3.5. 
Comparison of experiments 1 and 3 shows that when the concentrations of HCA and Cit are equal, 
the MSL increases from 0.75 to 1.20 mM Na2Ox, indicating the inhibitory effect of HCA, but the 
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change in the MSL compared to experiment 2 is not as great. Thus, HCA alone has a bigger effect 
on the MSL than when Cit is present too. 
 
 
Comparison of experiments 1 and 4 shows that the addition of 0.5 mM HCA to the control urine 
has no effect on the MSL. However, when the concentration of HCA is increased to 1.0 mM 
(experiment 5), the MSL increases to 1.20. This indicates that the effective concentration of HCA 
for retarding crystallisation is 1.0 mM. 
 
Comparison of the MSL in experiment 1 with the MSL in experiments 2, 3, 4, and 5 shows that 
the biggest change in the CaOx MSL occurred when HCA was present in the absence of Cit 
(experiment 1 vs experiment 2). 
From these results, it is clear that HCA is stronger than Cit at preventing CaOx crystallisation, and 
that a concentration of at least 1 mM HCA is needed for it to be effective. These results are 
expected as the potentiometric results show that HCA is a better chelator of Ca(II) than citrate. 
Thus, one would expect it to lower the concentration of free Ca(II) in AU, which in turn would 
increase the CaOx MSL. These results confirm the literature findings that HCA is more effective 
than citrate in preventing crystallisation [5,7,10] and demonstrate a thermodynamic role for HCA in 
retarding CaOx crystallisation. 
 
 





5.4. Measurement of CaOx crystallisation kinetics 
5.4.1. Methods 
Total crystallisation kinetics was determined in samples by adding Na2Ox (1 ml per 10 ml samples) 
at a concentration of 0.15 mM above the previously determined MSL (thus inducing 
crystallisation). In this method, 10 ml of each AU sample was incubated in a water bath with 
shaking at 37°C. The absorbance at 620 nm was measured at time zero and every 10 minutes 
over 120 minutes. 
CaOx crystals kinetics were determined by plotting the absorbance against time. The rate of CaOx 
crystallisation was determined from the slope of the curve. [11] Gradients were determined for the 
time periods during which the curve showed a constant linear increase, as this is indicative of 
steady crystallisation. 
In addition to the rate of crystallisation, a second parameter, the crystallisation induction time, was 
also measured. This corresponds to the time taken for crystallisation to be detected (sudden 
increase in absorbance) after the addition of Na2Ox. 
CaOx crystallisation kinetics and induction times were determined in three experiments involving 
the following solutions: 
(I) AU control. 
(II) AU control + 0.5 mM HCA. 
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(III) AU control + 1.0 mM HCA. 
  
Experiment (I) was performed in duplicate while experiments (II) and (III) were performed in 
triplicate. 
5.4.2.Results 
Experiment (I). Artificial urine (Control) 
The absorbance vs time graph is shown in Figure 5.6. Absorbance (i.e., crystallisation) increased 
after 50 minutes. The gradient was determined for the time period 50-120 min because the graph 
showed a linear increase (corresponding to a steady increase in crystallisation rate) during this 




































AU1: 0.0122 ± 0.0001
AU2: 0.0193  ± 0.0001





Experiment (ii). AU + 0.5 mM HCA 
 
The kinetic plots for the triplicate experiments in AU containing 0.5 mM HCA are shown in Figure 
5.7. Absorbance (i.e. crystallisation) increased immediately (induction time = 0). Gradients were 
determined during the period 0–70 min. The results show excellent repeatability for the 





 Figure 5.7. Absorbance versus time for CaOx crystallisation kinetics in AU containing 0.5  
 mM HCA. 






Experiment (iii). AU + 1.0 mM HCA 
The kinetic plots for the triplicate experiments in AU containing 1 mM HCA are shown in Figure 
5.8. Absorbance (i.e. crystallisation) increased after an induction time of 10 minutes in each sample. 
Gradients were determined during the period 20–70 min. The results show excellent repeatability for 











                Figure 5.8. Absorbance versus time for CaOx crystallisation kinetics in AU containing  
 1.0 mM HCA. 
 
 
Gradients ± SE 
AU1:0.0035 ± 0.0001 
AU2:0.0036 ± 0.00013  
AU3:0.0038 ± 0.00014 
 

















                 
 Figure 5.9. CaOx crystallisation rates as a function of HCA concentration in AU. 
 
It can be seen that the crystallisation rate increases with increasing HCA concentration. In addition, 
induction times appear to decrease dramatically after the addition of HCA irrespective of the 
latter’s concentration. Both of these effects are regarded as being favorable in terms of reducing 
the risk of CaOx stone formation. Firstly, a decrease in the induction time means that crystals start 
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crystallisation rate means the small crystal formed in AU continue to form more rapidly. This 
reduces the supersaturation rapidly, and this is good because, in vivo, crystals would pass through 
the urinary tract prior to aggregation. [13, 14] As in a previous chapter, it was shown that HCA is a 
strong chelator of Ca+2 to form [Ca(HCA)]-. This [Ca(HCA)]- complex reduced the CaOx 




In the study described in this chapter, the thermodynamic and kinetic effects of HCA on the CaOx 
metastable limit and the overall rate of CaOx crystallisation respectively were investigated. 
For HCA to be an effective therapy for kidney stones, it must be secreted in the urine. A previous 
study by Jahi and et al.[15],[8] revealed that HCA was detectable in blood and urine, making it a 
very good candidate as a stone therapeutic.[6]  Various trials of HCA in humans have reported 
HCA to be well tolerated, with no important dangerous side-effects.[7] 
As regarding crystallisation propensity, the CaOx MSL is defined as the capability of the solution 
to resist spontaneous nucleation. [9] In the present study, the effect of two different concentrations 
of HCA on MSL values was investigated. The addition of 1 mM HCA in AU leads to an increase 
in the CaOx MSL, indicating that it retards crystal nucleation at this concentration. This is 
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encouraging as it suggests that HCA might achieve the same result in vivo when administered to 
humans.  
 
For the investigation of crystallisation kinetics, the addition of 0.5 mM and 1 mM HCA to AU 
increased the rate of CaOx crystallisation. As stated previously, this is a favorable outcome 
because it suggests that small crystals would be formed rapidly (to reduce the supersaturation) 
[13]
, allowing them to pass relatively quickly and harmlessly through the urinary tract in the event 
of HCA being ingested. 
[13, [16]   This supports the notion that investigations involving AU help 
provide insight into protocols and conditions applied in vivo. [9] 
The previous review by Kim et al.[6] reported that the calcium-binding capacity of HCA and 
citrate at pH 5 to 7 and at concentrations up to 3 mM were not significantly different. However, the 
results of the present study showed the calcium-binding capacity of HCA is significantly greater 
than citrate (Chapter 2). A possible explanation for the lack of agreement between the two studies 
could be that in their measurement of HCA as a calcium complexing agent, Kim et al. used a 
calcium ion-specific electrode to measure residual concentrations of Ca2+, whereas, in the present 
study, actual stability constants were determined by potentiometric titration using a pH glass 
electrode. Kim et al. also reported that there was no difference between the CaOx MSL of urine 
in the presence of HCA and Cit whereas the present study demonstrated that HCA significantly 
affects this thermodynamic factor and that it does so to a greater extent than Cit. A possible 
explanation for this difference is that Kim et al. estimated crystallisation visually whereas, in the 
present study, crystallisation was measured photometrically. Thus, regarding both differences 
     
137 
 
between the studies (Ca-binding capacity and CaOx MSL), more sensitive techniques were used 
in the present study. 
  
In conclusion, the results obtained from the studies described here are important for two reasons. 
Firstly, stability constants for Ca-HCA complexation are reported for the first time. 
Secondly, the findings of favorable effects by HCA on retarding CaOx crystallisation indicate its 
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                                      Chapter Six 







The inhibition of urinary kidney stone formation can occur via a thermodynamic and/or kinetic 
route. The present study aimed to establish whether hydroxycitric acid citrate affects and/or 
inhibits calcium oxalate crystallisation and, if so, how it achieves this and how it compares with 
inhibition by citrate. Since the equilibrium constants of HCA with H+ and Ca2+ are unknown, the 
first step in the investigation was to measure these using glass electrode potentiometry. The 
thermodynamic binding constants for complexes for Ca(II)-HCA showed three species with log 
equilibrium constants (ML =   3.93, MLH2 =   3.32, and MLH  = 4.51) all higher than those for 
citrate.[1]  Equilibrium constants for these three species are being reported here for the first time 
and hence will be invaluable for future speciation and modelling projects involving calcium and 
HCA. 
Since HCA forms more stable complexes than citrate, it was of fundamental chemical interest to 
determine the structure of the different species. This was attempted using 1H-NMR, as described 
in Chapter 3. The results showed all protons shifted in response to changes in pH. Thus these data 
could not be used to estimate the pa values of HCA or to assign protonation sites to individual 
microstates. 
Solution structures of metal (Ca2+, Mg2+, and Zn2+)-HCA complexes were also investigated using 
1H-NMR, the idea being that those protons closest to the coordination site would be most affected 




(Chapter 3). On the addition of the metal ion, however, all the peaks shifted and/or broadened. 
Shifting of the proton signals is due to the inductive effect of the metal ion. Since none of the 
metal ions is paramagnetic, it was concluded that the broadening must be exchange broadening. 
That is, several different structural isomers of a species must exist simultaneously in solution. 
Since the chemical shifts of the various isomers will be different, rapid or intermediate (on the 
NMR time-scale) exchange between them will lead to signal broadening. Thus, the NMR results 
were inconclusive or showed that even for the metal complexes, several microstates co-exist in 
solution. Indeed, it is concluded that the existence of these microstates is a contributory factor for 
explaining the superior binding capacity of HCA to calcium. 
 
After the HCA-Ca equilibrium constants were determined, there was still a need to know if its 
complexes are strong enough to affect the speciation of Ca(II) in urine. This was modelled by 
including the measured equilibrium constants in the JESS thermodynamic database [2] and 
simulating their effect on urine. The results showed that a moderate concentration of 1 mM HCA 
significantly affects the in vitro speciation of calcium. At this concentration, in artificial urine, 
33% of the calcium is in the form of [Ca(HCA)]-. A result of this complexation of Ca2+ is that the 
free calcium concentration decreased. This, in turn, affected the calcium oxalate and phosphate 
speciation. 





Additionally, the SI values of different calcium salts as a function of HCA concentration were 
investigated. This showed that increasing the concentration of HCA decreased the SI of COM, 
hydroxyapatite, and brushite. Since various trials of HCA in humans have reported HCA to be 
well tolerated, with no important adverse events [2,3] these findings are important because they 
suggest that HCA could be considered for the treatment of calcium-containing kidney stones, 
provided that its effect on crystal inhibition could be demonstrated in in vitro experiments. This 
was achieved in studies described in Chapter 5. 
 
The results of the in vitro experiments showed that the addition of 1 mM HCA to artificial urine 
leads to an increase in the CaOx MSL, indicating that it retards crystallisation. This is a 
thermodynamic effect governed by the saturation of CaOx. 
In the kinetic experiments, the addition of 0.5 mM and 1 mM HCA to AU increased the rate of 
CaOx crystallization. This is a favourable outcome because it suggests that small crystals would 
be formed rapidly (thereby reducing the supersaturation), allowing them to pass relatively 
quickly and harmlessly through the urinary tract in an in vivo situation. This observation is 
supported by the decrease in the induction time with increasing concentrations of HCA. Since 
induction time measure how long it takes for crystallisation to be detected after exceeding the 
MSL, a reduction in this time indicates a more rapid formation of crystals to reduce 
supersaturation. 





Limitations of the present study include 
 
1. The use of mercantile salts instead of HCA extracted from the plant (Garcinia) might have                                  
affected the result. 
2. The experimental crystallisation work in the present study needs to be concluded with in vivo 
     studies in humans. 
 3.The experimentally used 1 mM HCA and showed the effect of HCA in vitro ,but this 1 mM HCA may be 
enough or not to in vivo ,so what is the convenient volume of doses per day this could be used from HCA to 
prevention measures from kidney stones diseases . 
 
Despite these limitations, it is concluded that the studies described in this thesis have shown that 
HCA plays thermodynamic and kinetic roles in decreasing important crystallisation danger factors 
for CaOx kidney stone formation. This is the first time that these effects have been demonstrated 
theoretically and experimentally for HCA. Thus, future studies involving the administration of 
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